Latest Industry Insights

Technology Networks recently had the pleasure of speaking with Abpro’s CEO, Ian Chan, to learn more about the company’s research and development pipeline. Chan discusses in detail the development of ABP-300, a monoclonal antibody that neutralizes SARS-CoV-2 by associating with the virus’s spike protein.

We spoke to Dr Lorna Ewart, Emulate’s executive vice president of science, to learn more about the limitations of traditional inflammatory intestinal disease models, what makes the Colon Intestine-Chip a more relevant model and how it can be used to investigate potential drug targets.

A new body of work published in Science Translational Medicine outlines the preclinical testing of a microRNA-based gene therapy for Huntington's disease – AMT-130 – in minipigs.

In this interview, Technology Networks spoke with Neal Goodwin, PhD, Chief Scientific Officer at Teknova, to learn more about current bioprocessing and bioproduction trends in the cell and gene therapy space. Goodwin also discusses the impact of the COVID-19 pandemic on the biopharmaceutical sector and highlights how the industry has united to contribute to the development of vaccines at this critical time.

While S-ketamine has now become licensed as the antidepressant nasal spray Spravato, research into its mirror molecule has been more limited. Now, drug developers say that R-ketamine could potentially deliver a more targeted action with fewer side effects than its more popular twin.

Technology Networks had the pleasure of speaking with Ki-Sung Kwon, head of the R&D unit at Celltrion to learn more about therapeutic versus preventive strategies against COVID-19 and the company's monoclonal antibody-based therapeutic – CT-P59 – that is currently being developed against COVID-19.

Animal-free testing methods are being increasingly explored and implemented as an alternative to animal models, in efforts to provide a more accurate prediction of a drug candidate’s efficacy and safety. InSphero recently hosted a virtual roundtable discussion on the topic of animal-free testing. Technology Networks had the pleasure of speaking with Armin Wolf, chief scientific officer at InSphero, to learn more about the topics discussed.

Technology Networks recently interviewed Benjamin Oakes, co-founder, president and CEO at Scribe, to learn more about the company's next steps in "fulfilling the promise of CRISPR" and how it will navigate some of the challenges associated with developing CRISPR-based therapeutics, including efficacy, scale-up and high costs.

We interviewed Jan Davidson MD., PhD., the newly appointed chief medical officer at Wugen to learn more about the company's agreement with Washington University to further their Memory NK Cell program.

Western blotting has been a core technique in molecular biology for many years, however, optimization and reproducibility can be problematic. We spoke to Dr Alexandre Lucas about the automation of western blotting and the difference this advance is making to research.